INTRODUCTION

Airway mucus is a thin gel-like layer lining the airway luminal surface that consists of water, ions, and various molecules that show antimicrobial and anti-oxidative activities (Adler and Li, 2001). Mucus glycoproteins (mucins) that confer mucus viscoelasticity form a major biological macromolecular component of mucus. In normal lung physiology, airway mucus exerts its function as a physical defensive barrier against airway epithelial damage induced by inhaled dust, irritating gases, and microbes, such as bacteria and viruses, thereby protecting the pulmonary system (Lillehoj and Kim, 2002). However, under the pathological state of the pulmonary system, such as chronic obstructive pulmonary diseases, cystic fibrosis, and asthma, the hyperproduction and/or hypersecretion of airway mucus, indicating the changes in mucin quality or quantity, have been reported to compromise the host defense system, ultimately leading to increased morbidity and mortality (Rose and Voynow, 2006). Although mucolytics, expectorants, and glucocorticoids have been clinically used for the management of abnormal airway mucus secretion, several drawbacks are associated with their use, including rebound mucus hypersecretion due to airway luminal wall irritation and various adverse side effects (Li et al., 2020). Thus, it is necessary to develop novel agents that regulate the production and/or secretion of mucins by controlling their biosynthesis and/or degradation.

Achieving this may require investigating natural compounds (derived from diverse medicinal plants that are used empirically for alleviating inflammatory pulmonary diseases), with respect to the activity to regulate abnormal secretion and/or production of mucins. We have reported various natural products that modulate the gene expression, production, and secretion of airway mucins (Kim et al., 2012; Seo et al., 2014; Choi et al., 2019; Li et al., 2020).

According to a multitude of reports, eriodictyol, a flavanone, is present in numerous vegetables, fruits, and medicinal plants; moreover, it shows a broad range of biological activities, including antioxidative, antineoplastic, anti-inflammatory, antidiabetic, neuroprotective, antiobesity, cardioprotective, and hepatoprotective activities (Islam et al., 2020). Eriodictyol exerted anticancer effects on human lung cancer cells (Zhang et al., 2019). Eniafe et al. (2018) suggested that eriodictyol may be used for the long-term regulation of asthmatic contraction of bronchial smooth muscle. In addition, Deshpande et al. (2020) suggested that eriodictyol can be used as a potential regulator for coronavirus disease 2019 via in silico analysis.

This study, we investigated whether eriodictyol exerts an effect on the production and gene expression of MUC5AC mucin in human pulmonary epithelial NCI-H292 cells. The cells were pretreated with eriodictyol for 30 min and then stimulated with phorbol 12-myristate 13-acetate (PMA) for 24 h. The effect of eriodictyol on PMA-induced nuclear factor kappa B (NF-κB) signaling pathway was also investigated. Eriodictyol suppressed the MUC5AC mucin production and gene expression induced by PMA via suppression of inhibitory kappa Bα degradation and NF-κB p65 nuclear translocation. These results suggest that eriodictyol inhibits mucin gene expression and production in human airway epithelial cells via regulation of the NF-κB signaling pathway.

Key Words: MUC5AC, Pulmonary mucin, Eriodictyol

Abstract

In this study, we investigated whether eriodictyol exerts an effect on the production and gene expression of MUC5AC mucin in human pulmonary epithelial NCI-H292 cells. The cells were pretreated with eriodictyol for 30 min and then stimulated with phorbol 12-myristate 13-acetate (PMA) for 24 h. The effect of eriodictyol on PMA-induced nuclear factor kappa B (NF-κB) signaling pathway was also investigated. Eriodictyol suppressed the MUC5AC mucin production and gene expression induced by PMA via suppression of inhibitory kappa Bα degradation and NF-κB p65 nuclear translocation. These results suggest that eriodictyol inhibits mucin gene expression and production in human airway epithelial cells via regulation of the NF-κB signaling pathway.
using molecular docking technology. However, there are no studies about the potential effect of eriodictyol on mucin production and mucin gene expression in airway epithelial cells. Among the many subtypes of human mucins, mucin 5AC (MUC5AC) is known as a major type of airway mucin (Lillehoj and Kim, 2002). In this study, we investigated the effect of eriodictyol on MUC5AC mucin production and gene expression induced by phorbol ester in NCI-H292 cells. The human pulmonary mucopeidermoid cell line NCI-H292 is often used for identifying the signaling pathways involved in airway mucin production and gene expression (Li et al., 1997; Takeyama et al., 1999, 2003). Thus, to elucidate the mechanism of eriodictyol, we examined whether it exerts any effect on phorbol ester-induced activation of the NF-κB signaling pathway in NCI-H292 cells.

MATERIALS AND METHODS

Materials

All chemicals used in this study were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise stated. Eriodictyol (AV-H19076; purity: 98.0%) was purchased from Avention (Incheon, Korea). Anti-NF-κB p65 (sc-8008), anti-β-actin (sc-8432), and anti-inhibitory kappa Bα (IκBα; sc-371) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phospho-inhibitory kappa B kinase (IKK) α/β (Ser176/180; #2687) and phospho-specific anti-IκBα (serine 32/36; #9246) antibodies were purchased from Cell Signaling Technology Inc (Danvers, MA, USA). Anti-nuclear matrix protein p84 (ab-487) antibody was purchased from Abcam (Cambridge, MA, USA). Goat anti-mouse IgG (#401215) and goat anti-rabbit IgG (#401315) were purchased from Calbiochem (Carlsbad, CA, USA) and used as the secondary antibody.

NCI-H292 cell culture

NCI-H292 cells were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal bovine serum (FBS), penicillin-streptomycin mixture (100 units/mL and 100 µg/mL, respectively), and hydroxyethyl piperazineethanesulfonic acid (25 mM) at 37°C in a water-jacketed humidified incubator (95% CO2, 95% air). For serum deprivation, confluent cells were washed with phosphate-buffered saline (PBS) and then cultured in RPMI 1640 with 0.2% FBS for 24 h.

Eriodictyol treatment of cells

After serum deprivation, the cells were pretreated with varying concentrations of eriodictyol for 30 min and treated with phorbol 12-myristate 13-acetate (PMA) at 10 ng/mL for 24 h in serum-free RPMI 1640. Eriodictyol was dissolved in dimethyl sulfoxide and treated in culture medium (final concentration of dimethyl sulfoxide was 0.5%). The final pH values of these solutions were between 7.0 and 7.4. The culture medium and 0.5% dimethyl sulfoxide did not affect mucin gene expression, production, and expression and activity of molecules involved in NF-κB signaling pathway in NCI-H292 cells. After 24 h, the cells were lysed with buffer solution containing 20 mM Tris, 0.5% NP-40, 250 mM NaCl, 3 mM ethylenediaminetetraacetic acid (EDTA), 3 mM ethylene glycol tetraacetic acid (EGTA), and protease inhibitor cocktail (Roche Diagnostics, IN, USA) and were collected to measure the production of MUC5AC glycoproteins in a 24-well culture plate. Total RNA was extracted to determine MUC5AC gene expression in a six-well culture plate via reverse transcription polymerase chain reaction (RT-PCR). For western blot analysis, the cells were treated with eriodictyol for 24 h and PMA for 30 min.

Quantitative analysis of MUC5AC mucin

Airway MUC5AC mucin production was measured using enzyme-linked immunosorbent assay. Cell lysates were prepared with PBS at a 1:10 dilution, and 100 µL of each sample was incubated at 42°C in a 96-well plate until dried. The plates were washed three times with PBS, blocked with 2% bovine serum albumin (fraction V) for 1 h at room temperature, and then washed three times with PBS. The plates were then incubated with 100 µL 45M1, a mouse monoclonal MUC5AC antibody (NeoMarkers, CA, USA), which was diluted at 1:200 with PBS containing 0.05% Tween 20. After 1 h, the wells were washed three times with PBS, and 100 µL of horseradish peroxidase-antibody-mouse IgG conjugate (1:3,000) was dispensed into each well and left to incubate for 1 h, after which the plates were washed three times with PBS. Color reaction was developed with 3.3’5,5’-tetramethylbenzidine peroxide solution and stopped with 1 N H2SO4. The absorbance was measured at 450 nm.

Isolation of total RNA and RT-PCR

Total RNA was isolated using the easy-BLUE Extraction Kit (INIRION Biotechnology, Inc., Gyeonggi, Korea) and reverse transcribed using AccuPower RT Premix (BIONEER Corporation, Daejeon, Korea) according to the manufacturer’s instructions. Two micrograms of total RNA were primed with 1 µg of oligo (dT) in a final volume of 50 µL (RT reaction). Two microliters of the RT reaction product were PCR-amplified in a 25 µL using Thermoprime Plus DNA Polymerase (ABgene, Rochester, NY, USA). RIG/S15 rRNA, which encodes a small ribosomal subunit protein, a housekeeping gene that was constitutively expressed, was used as a quantitative control. The following primers were used: MUC5AC, forward (5’-TGA TCA TCC AGC AGG GCT-3’) and reverse (5’-CCG AGC TCA GAG GAC ATA TGG G-3’); RIG/S15, forward (5’-TTG CAC AAG TTC ACC TAC C-3’) and reverse (5’-CGG GCC GGC CAT GCT TTA CG-3’). The PCR mixture was denatured at 94°C for 2 min followed by 40 cycles at 94°C for 30 s, 60°C for 30 s, and 72°C for 45 s. After PCR, 5 µL of the PCR product was subjected to 1% agarose gel electrophoresis and then visualized with ethidium bromide under a transilluminator.

Whole cell extract preparation

NCI-H292 cells (confluent in 100-mm culture dish) were pretreated for 24 h at 37°C with 1, 5, 10, or 20 µM of eriodictyol and then stimulated with PMA (50 ng/mL) in serum-free RPMI 1640 for 30 min. After eriodictyol treatment, media were aspirated and the cells were washed with cold PBS. For the cell collection, the cells were scraped and centrifuged at 3,000 rpm for 5 min. After the supernatant was discarded, the cell
pellet was mixed with radioimmunoprecipitation assay buffer (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS)) for 30 min with continuous agitation. The lysate was centrifuged in a microcentrifuge at 14,000 rpm for 15 min at 4°C. The supernatant was either used or immediately stored at −80°C. The amount of protein in the extract was quantified using the Bradford method.

**Nuclear and cytosolic extract preparation**

After treatment with eriodictyol, the cells were harvested using trypsin-EDTA solution and then centrifuged in a microcentrifuge at 1,200 rpm for 3 min at 4°C. After the supernatant was discarded, the cell pellet was washed by suspending in PBS. The cytoplasmic and nuclear protein fractions were extracted using NE-PER® nuclear and cytoplasmic extraction reagent (Thermo-Pierce Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Both extracts were stored at −20°C. The amount of protein in the extracts was quantified using the Bradford method.

**Western blot analysis**

Whole cell, cytosolic, and nuclear extracts containing proteins (each 50 µg) were subjected to 10% SDS polyacrylamide gel electrophoresis and then transferred onto a polyvinylidene difluoride membrane. The blots were blocked with 5% skimmed milk and probed with the appropriate primary antibody in blocking buffer overnight at 4°C. The membrane was washed with PBS and then probed using the horseradish peroxidase-conjugated secondary antibody. Immunoreactive bands were detected using an enhanced chemiluminescence kit (Pierce ECL western blotting substrate; Thermo-Pierce Scientific).

**Statistical analysis**

The means of individual groups were converted to percent control and expressed as the mean ± standard error of the mean. The difference between groups was assessed using one-way analysis of variance and the Holm-Sidak test as a post-hoc test. A p-value < 0.05 was considered significantly significant.

**RESULTS**

**Effect of eriodictyol on PMA-induced MUC5AC gene expression and mucin production**

Eriodictyol suppressed PMA-induced MUC5AC gene expression (Fig. 1) and mucin production (Fig. 2), with the latter being dose dependent. As shown in Fig. 2, the amounts of MUC5AC mucin in the cells of eriodictyol-treated cultures were as follows: control, 100 ± 2%; 10 ng/mL of PMA alone, 185 ± 3%; PMA plus 1 µM eriodictyol, 182 ± 3%; PMA plus 5 µM eriodictyol, 145 ± 2%; PMA plus 10 µM eriodictyol, 102 ± 4%; PMA plus 20 µM eriodictyol, 70 ± 1%. Cell viability was assessed using the sulforhodamine B assay, which revealed that there was no cytotoxic effect of eriodictyol at concentrations of 1, 5, 10, or 20 µM (data not shown).

**Effect of eriodictyol on PMA-induced IKKα/β and IκBα phosphorylation and IκBα degradation**

To activate NF-κB, PMA induces the phosphorylation of IKK, which sequentially phosphorylates IκBα. The phosphorylated IκBα dissociates from NF-κB and is degraded. Therefore, we tested whether eriodictyol affects the PMA-induced phosphorylation of IκKαβ and IκBα and degradation of IκBα. As shown in Fig. 3, eriodictyol attenuated PMA-stimulated IκKαβ phosphorylation by controlling the phosphorylation of the serine 176/180 moiety of IκKαβ. PMA treatment increased the phosphorylation of IκBα, whereas eriodictyol treatment suppressed its phosphorylation. Moreover, PMA treatment increased the degradation of IκBα, whereas eriodictyol treatment suppressed its degradation.

**Effect of eriodictyol on PMA-induced NF-κB p65 phosphorylation and nuclear translocation**

After its activation, NF-κB translocates from the cytosol to the nucleus, followed by binding to a specific DNA sequence.
Concentration unit is μM.

This NF-κB/DNA assembly recruits RNA polymerase, and the resulting mRNA is translated into the specific proteins, including MUC5AC mucus. The transcriptional activity of NF-κB p65 is dependent on its phosphorylation. As shown in Fig. 4, PMA treatment increased the phosphorylation of p65, whereas eriodictyol treatment suppressed its phosphorylation. Eventually, eriodictyol decreased the nuclear translocation of NF-κB p65 stimulated by PMA.

**DISCUSSION**

As mentioned above, mucolytics, expectorants, and glucocorticoids have been utilized for pharmacotherapy of pulmonary diseases that exhibit hypersecretion of airway mucus; however, these drugs have limited clinical efficacy in regulating such diseases and elicit diverse side effects (Li *et al.*, 2020). Thus, it is essential to develop novel agents that regulate production and/or secretion of mucus by controlling their biosynthesis and/or degradation. Achieving this may require investigating natural compounds (derived from diverse medicinal plants that are used empirically for alleviating inflammatory pulmonary diseases), with respect to the activity to regulate abnormal secretion and/or production of mucus. Our results showed that eriodictyol, a flavonoid with anti-inflammatory activity, decreased MUC5AC gene expression and mucin production stimulated by PMA (Fig. 1, 2). These results suggest that eriodictyol can regulate the gene and protein expression of pulmonary mucin by directly acting on airway epithelial cells. This is the first study to report about the regulatory activity of eriodictyol on airway mucin production.

Eriodictyol was reported to suppress the IL-1β-mediated inflammation of chondrocytes, by attenuating NF-κB activation, and to downregulate the IL-1β-stimulated overproduction of PGE2, nitric oxide, and COX-2 (Wang *et al.*, 2018). In the lipopolysaccharide-mediated acute lung injury mice model, eriodictyol dramatically reduced the expression levels of IL-6, PGE2, IL-1β, and TNF-α in the bronchoalveolar lavage fluid. In addition, the activation of COX-2/NLRP3/NF-κB and Nrf2 signaling was attenuated by eriodictyol (Wang *et al.*, 2020). Notably, a similar report confirmed that eriodictyol could function as an anti-inflammatory agent by protecting against *Staphylococcus aureus*-mediated lung injury (Xuewen *et al.*, 2018). These reports indicate the need to investigate the mechanism of action of eriodictyol involved in mucin gene expression and production, focusing on the NF-κB signaling pathway.

As a multifunctional transcription regulator, NF-κB signaling commonly exists in eukaryotic cells. NF-κB activation occurs by preferentially inducing the phosphorylation of the IKKs, which then activate IkBα phosphorylation. Consequently, the dissociated form of phosphorylated IkBα accumulates and is degraded by the proteasome. NF-κB subunits (p65 and p50) are then released and enter the nucleus, where they bind to DNA (Nie *et al.*, 2012; Liu *et al.*, 2020). The NF-κB signaling pathway plays a crucial role in mediating the biological functions associated with immunity and inflammation (Huang *et al.*, 2018; Lee *et al.*, 2019; Shang *et al.*, 2019). Under pathological airway conditions, NF-κB was found to be involved in mucin hypersecretion and cytokine activity regulation (Liu *et al.*, 2020), and its abnormal activation has been observed in patients with asthma (Huang *et al.*, 2018). Several groups of scientists reported that the gene expression and production of MUC5AC mucin might be induced by the inflammatory mediators that stimulate the activity of transcription factors including NF-κB (Fujisawa *et al.*, 2009; Kurakula *et al.*, 2015; Garvin...
et al., 2016). PMA induces airway MUC5AC gene expression and mucin production, and NF-κB signaling is involved in this activity (Ishinaga et al., 2005; Laos et al., 2006; Wu et al., 2007; Kim et al., 2012).

In our study, eriodictyol suppressed NF-κB p65 phosphorylation and nuclear translocation by acting on the steps of the phosphorylation and degradation of IkBα, in human airway epithelial cells (Fig. 3, 4). Therefore, the pharmacological effect of eriodictyol may be partly exerted on MUC5AC gene expression and mucin production by reducing IkBα degradation and NF-κB p65 nuclear translocation.

Collectively, these results indicate that the inhibitory activity of eriodictyol on airway mucin gene expression and production might be mediated by controlling PMA-stimulated IkBα degradation and NF-κB p65 nuclear translocation. Therefore, eriodictyol could possibly be used as an effective novel mucoregulator for inflammatory pulmonary diseases. It is desirable that eriodictyol could possibly be used as an effective novel mucoregulator for inflammatory pulmonary diseases. It is desirable to modify the chemical structure of eriodictyol to obtain an optimal compound that will show the most effective regulatory effect on the secretion and/or production of pulmonary mucus.

CONFLICT OF INTEREST

The authors have declared that there is no conflict of interest.

ACKNOWLEDGMENTS

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2014R1A6A1029617).

REFERENCES


